<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201202159026N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-04-05</date_registration>
      <primary_sponsor>Anesthesia Research Center, Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effect of clonidine on intraoperative consumption of propofol</public_title>
      <acronym></acronym>
      <scientific_title>The effect of pretreatment with clonidine on propofol consumption in opium&#13;
abuser and non-abuser patients undergoing elective leg surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-04-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9650</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>general anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: In first Intervention(case) group (non addicted)&amp; second Intervention(case) group (addicted)&#13;
&#13;
tab clonidine(5mic/kg)90min before operation will prescribe and then&#13;
The patients will anesthetize using the same predetermined method, The depth of anesthesia will controll and keep  between 40 and 60(range of surgical anesthesia ) by recording the Bispectral index. If any deviation will note (BIS&gt;60 or BIS&lt;40) &amp; by increasing or decreasing dose of propofol the level of anesthesia will correct to reach the determined range.Finally,during&amp;after termination of the surgery, the results for the length of operation, the detailed BIS number recordings, the total administered dose of propofol ,the length of anesthesia, the patients, Recovery time, and Intraoperative bleeding will record. Intervention 2: In first Control(placebo) group(non addicted)&amp; second Control(placebo) group(addicted)&#13;
&#13;
tab Vit. C(2mg/kg)90min before operation will prescribe and then&#13;
The patients will anesthetize using the same predetermined method, The depth of anesthesia will controll and keep  between 40 and 60(range of surgical anesthesia ) by recording the Bispectral index. If any deviation will note (BIS&gt;60 or BIS&lt;40) &amp; by increasing or decreasing dose of propofol the level of anesthesia will correct to reach the determined range.Finally,during&amp;after termination of the surgery, the results for the length of operation, the detailed BIS number recordings, the total administered dose of propofol ,the length of anesthesia, the patients, Recovery time, and Intraoperative bleeding will record.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Davood Ommi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madani street- Imam Hossein hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 7756 7840</telephone>
        <email>davoodommi@yahoo.com</email>
        <affiliation>Anesthesia departement , Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Alireza Mirkheshti</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Madani street, Imam Hossein hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 7756 7840</telephone>
        <email>alimirkheshti@yahoo.com</email>
        <affiliation>Anesthesia departement, Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria&#13;
patient informed written consent for entering study; American Society of Anesthesiologists (ASA)&#13;
classification score 1 or 2 (I or II); age range of 18 to 65 years and maximum length of surgery&#13;
up to 180 minutes  &#13;
Exclusion criteria &#13;
patient disagreement; ASA class&gt;2; SBP&gt;140mmhg or SBP&lt;90mmhg; maximum length of surgery&gt;180min; age&lt;18y or age&gt;65y; cardiac arrhythmias; SaO2&lt;90%; history of egg or propofol sensitivity; multiple trauma; addict in withdrawal phase&#13;
coagulopathy.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In first Intervention(case) group (non addicted)&amp; second Intervention(case) group (addicted)&#13;
&#13;
tab clonidine(5mic/kg)90min before operation will prescribe and then&#13;
The patients will anesthetize using the same predetermined method, The depth of anesthesia will controll and keep  between 40 and 60(range of surgical anesthesia ) by recording the Bispectral index. If any deviation will note (BIS&gt;60 or BIS&lt;40) &amp; by increasing or decreasing dose of propofol the level of anesthesia will correct to reach the determined range.Finally,during&amp;after termination of the surgery, the results for the length of operation, the detailed BIS number recordings, the total administered dose of propofol ,the length of anesthesia, the patients, Recovery time, and Intraoperative bleeding will record.</i_keyword>
      <i_keyword>In first Control(placebo) group(non addicted)&amp; second Control(placebo) group(addicted)&#13;
&#13;
tab Vit. C(2mg/kg)90min before operation will prescribe and then&#13;
The patients will anesthetize using the same predetermined method, The depth of anesthesia will controll and keep  between 40 and 60(range of surgical anesthesia ) by recording the Bispectral index. If any deviation will note (BIS&gt;60 or BIS&lt;40) &amp; by increasing or decreasing dose of propofol the level of anesthesia will correct to reach the determined range.Finally,during&amp;after termination of the surgery, the results for the length of operation, the detailed BIS number recordings, the total administered dose of propofol ,the length of anesthesia, the patients, Recovery time, and Intraoperative bleeding will record.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Intraoperative consumption of propofol. Timepoint: During operation. Method of measurement: miligram.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Intraoperative bleeding. Timepoint: During operation. Method of measurement: Mililiter.</sec_outcome>
      <sec_outcome>Recovery time. Timepoint: At the end of anesthesia. Method of measurement: Minutes.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Anesthesia Research Center, Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2011-01-23</approval_date>
        <contact_name>Shahid Beheshti University of Medical Sciences Ethics Committee</contact_name>
        <contact_address>Velenjak Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
